Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
OBJECTIVE
Recent studies indicate that circulating calprotectin may serve as a biomarker in some cancers. We investigated whether this is the case for ovarian neoplasms.


METHODS
Calprotectin was analyzed with an enzyme-linked immunosorbent assay in EDTA-plasma collected prior to surgery from women with ovarian carcinomas (n = 89), borderline ovarian tumors (BOT, n = 39), and benign ovarian tumors (n = 71). Serum CA 125 was analyzed in the same study population.


RESULTS
Median plasma calprotectin concentration was elevated in ovarian carcinoma, compared with controls, as well as compared with BOT (both P < .001). A positive correlation was found between CA 125 and calprotectin concentrations in ovarian carcinoma. Receiver operating characteristic curves demonstrated a larger area under the curve for CA 125 (0.85) as compared with calprotectin (0.70).


CONCLUSIONS
Plasma calprotectin is elevated in invasive ovarian cancer, but when used as a tumor marker, it is inferior to CA 125.
Ødegaard
Elin
E
Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway.
Davidson
Ben
B
Elgaaen
Bente Vilming
BV
Fagerhol
Magne K
MK
Engh
Vibeke
V
Onsrud
Mathias
M
Staff
Anne Cathrine
AC
D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D039841:Leukocyte L1 Antigen Complex / Q000097:blood*; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis*; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D039841:Leukocyte L1 Antigen Complex